Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.03
$0.03
$0.03
▼
$1.42
$1.60M2.964.85 million shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%0.00%0.00%0.00%-95.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.03
$0.03
$0.03
▼
$1.42
$1.60M2.964.85 million shsN/A
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
0.00%0.00%0.00%0.00%-95.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1.67
ReduceN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$390K4.10N/AN/A($0.15) per share-0.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.75N/AN/AN/AN/AN/A-65.54%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.13
1.96

Institutional Ownership

CompanyInstitutional Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%

Insider Ownership

CompanyInsider Ownership
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1053.29 million52.23 millionNot Optionable

Recent News About These Companies

HC Wainwright & Co. downgrades Iterum Therapeutics (ITRM)
March 31, 2026  |  msn.comhttps://www.msn.com/en-us/money/technology/hc-wainwright-co-downgrades-iterum-therapeutics-itrm/ar-AA1ZN9Pn
What's going on with Iterum Therapeutics stock Monday?
March 30, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/what-s-going-on-with-iterum-therapeutics-stock-monday/ar-AA1ZL5Du
Iterum files wind-up petition due to limited cash, inability to raise equity
March 27, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/iterum-files-wind-up-petition-due-limited-cash-inability-raise-equity-2026-03-27/
Iterum Therapeutics Announces Filing of Winding Up Petition
March 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/27/3263799/0/en/iterum-therapeutics-announces-filing-of-winding-up-petition.html
Iterum Therapeutics (ITRM) price target increased by 63.64% to 9.18
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/iterum-therapeutics-itrm-price-target-increased-by-63-64-to-9-18/ar-AA1ZwakV
Iterum Therapeutics Provides Business Update
February 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/02/13/3238074/0/en/iterum-therapeutics-provides-business-update.html
Iterum Therapeutics PLC
January 17, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/itrm/company-people?gaa_n=AWEtsqcpmwJcemEUHevKL7ci4WxE7YPnFfbLD5xHMnQcQe0MQnEdjzQyrqHe&gaa_ts=6924adcd
Iterum Therapeutics Provides Business Update
December 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/23/3209840/0/en/iterum-therapeutics-provides-business-update.html
Iterum Therapeutics Provides Business Update
December 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/17/3206944/0/en/iterum-therapeutics-provides-business-update.html
Iterum Therapeutics (ITRM) price target decreased by 21.43% to 5.61
December 7, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/iterum-therapeutics-itrm-price-target-decreased-by-21-43-to-5-61/ar-AA1RRf2W
Iterum Therapeutics Provides Business Update
December 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/05/3200651/0/en/iterum-therapeutics-provides-business-update.html
Iterum Therapeutics Provides Business Update
November 24, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/24/3193450/0/en/iterum-therapeutics-provides-business-update.html
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2025 Earnings Call Transcript
November 15, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/iterum-therapeutics-plc-nasdaqitrm-q3-2025-earnings-call-transcript-1646066/
Iterum Therapeutics sees cash runway into 2Q26
November 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/taxes/iterum-therapeutics-sees-cash-runway-into-2q26/ar-AA1Qs9AO
Iterum Therapeutics sees FY26 ORLYNVAH net product sales $5M-$15M
November 14, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/iterum-therapeutics-sees-fy26-orlynvah-net-product-sales-5m-15m/ar-AA1QsbSu
Iterum Therapeutics PLC (ITRM) Q3 2025 Earnings Call Highlights: Launch Success and Financial ...
November 14, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/iterum-therapeutics-plc-itrm-q3-210151197.html
Iterum Therapeutics plc (ITRM) Q3 2025 Earnings Call Transcript
November 14, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4843866-iterum-therapeutics-plc-itrm-q3-2025-earnings-call-transcript
Iterum Therapeutics Reports Third Quarter 2025 Financial Results
November 14, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/14/3188192/0/en/iterum-therapeutics-reports-third-quarter-2025-financial-results.html
A Glimpse of Iterum Therapeutics's Earnings Potential
November 14, 2025  |  benzinga.comhttps://www.benzinga.com/insights/earnings/25/11/48835873/a-glimpse-of-iterum-therapeuticss-earnings-potential
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
November 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/11/07/3183595/0/en/iterum-therapeutics-to-report-third-quarter-2025-financial-results-on-friday-november-14-2025.html
Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.03 0.00 (0.00%)
As of 09/18/2026

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas